Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Synthetic Vaccine for Triple-Negative Breast Cancer
NCT04879888Phase 1Completed
- Sponsor
- Universidad Nacional de Colombia
- Start
- Aug 2016
- Primary completion
- Dec 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peptide pulsed dendritic cell in triple negative breast cancer (TNBC), sponsored by Universidad Nacional de Colombia. Primary endpoint: Number of adverse effects. Started Aug 2016; status: completed.
02
Drugs
peptide pulsed dendritic cell
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04879888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879888.